Intra-Cellular Therapies, Inc. (ITCI)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Intra-Cellular Therapies, Inc. (ITCI)
Go deeper and ask any question about ITCI
Company Performance
Current Price
as of Sep 13, 2024$75.38
P/E Ratio
N/A
Market Cap
$7.97B
Description
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.
Metrics
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerITCI
- Price$75.38+0.21%
Trading Information
- Market Cap$7.97B
- Float93.47%
- Average Daily Volume (1m)471,323
- Average Daily Volume (3m)1,028,763
- EPS-$0.86
Company
- Revenue$564.53M
- Rev Growth (1yr)45.67%
- Net Income-$16.22M
- Gross Margin92.96%
- EBITDA Margin-17.10%
- EBITDA-$27.59M
- EV$6.10B
- EV/Revenue10.80
- P/EN/A
- P/S13.85